GW&K Investment Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.28M Sell
10,667
-284,664
-96% -$32.9M 0.01% 325
2025
Q4
$31.1M Buy
295,331
+12,221
+4% +$1.15M 0.27% 146
2025
Q3
$23.8M Sell
283,110
-17,170
-6% -$1.41M 0.21% 177
2025
Q2
$23.8M Sell
300,280
-4,321
-1% -$343K 0.21% 177
2025
Q1
$27.3M Buy
304,601
+62,041
+26% +$5.79M 0.25% 158
2024
Q4
$24.1M Sell
242,560
-40,333
-14% -$4.16M 0.21% 183
2024
Q3
$32.1M Sell
282,893
-4,417
-2% -$525K 0.27% 151
2024
Q2
$35.6M Sell
287,310
-5,426
-2% -$699K 0.33% 123
2024
Q1
$38.6M Sell
292,736
-2,786
-0.9% -$343K 0.34% 123
2023
Q4
$32.2M Buy
295,522
+45,877
+18% +$4.76M 0.3% 139
2023
Q3
$25.7M Buy
249,645
+248,584
+23,429% +$26.8M 0.26% 149
2023
Q2
$122K Buy
1,061
+789
+290% +$89.6K ﹤0.01% 351
2023
Q1
$29K Buy
272
+50
+23% +$5.4K ﹤0.01% 369
2022
Q4
$25K Hold
222
﹤0.01% 349
2022
Q3
$19K Sell
222
-531
-71% -$47.4K ﹤0.01% 344
2022
Q2
$69K Buy
753
+192
+34% +$17K ﹤0.01% 370
2022
Q1
$46K Buy
561
+259
+86% +$20.4K ﹤0.01% 381
2021
Q4
$23K Hold
302
﹤0.01% 368
2021
Q3
$23K Sell
302
-307
-50% -$23.3K ﹤0.01% 360
2021
Q2
$47K Sell
609
-177,499
-100% -$13.2M ﹤0.01% 352
2021
Q1
$13.1M Sell
178,108
-280,937
-61% -$20.7M 0.12% 213
2020
Q4
$35.8M Sell
459,045
-3,158
-0.7% -$242K 0.38% 120
2020
Q3
$36.6M Sell
462,203
-5,269
-1% -$413K 0.48% 75
2020
Q2
$34.5M Sell
467,472
-6,004
-1% -$452K 0.48% 68
2020
Q1
$34.8M Sell
473,476
-6,399
-1% -$503K 0.61% 46
2019
Q4
$41.6M Sell
479,875
-2,381
-0.5% -$196K 0.56% 52
2019
Q3
$38.7M Sell
482,256
-34,198
-7% -$2.74M 0.54% 49
2019
Q2
$41.3M Sell
516,454
-9,514
-2% -$728K 0.63% 35
2019
Q1
$41.7M Sell
525,968
-3,677
-0.7% -$275K 0.67% 33
2018
Q4
$38.6M Sell
529,645
-14,396
-3% -$1.02M 0.76% 31
2018
Q3
$36.8M Buy
544,041
+124,689
+30% +$7.94M 0.59% 49
2018
Q2
$24.3M Sell
419,352
-83,025
-17% -$4.68M 0.4% 107
2018
Q1
$26.1M Sell
502,377
-16,592
-3% -$896K 0.44% 92
2017
Q4
$27.9M Buy
518,969
+82,531
+19% +$4.58M 0.48% 86
2017
Q3
$26.7M Sell
436,438
-3,996
-0.9% -$242K 0.44% 100
2017
Q2
$26.9M Buy
440,434
+11,856
+3% +$722K 0.46% 100
2017
Q1
$26M Buy
428,578
+19,221
+5% +$1.17M 0.49% 92
2016
Q4
$23M Buy
409,357
+22,488
+6% +$1.32M 0.45% 97
2016
Q3
$23M Buy
386,869
+23,827
+7% +$1.39M 0.43% 100
2016
Q2
$20M Buy
363,042
+21,860
+6% +$1.16M 0.41% 102
2016
Q1
$17.2M Buy
341,182
+18,781
+6% +$920K 0.38% 107
2015
Q4
$16.2M Buy
322,401
+819
+0.3% +$41.3K 0.38% 108
2015
Q3
$15.2M Buy
321,582
+7,678
+2% +$408K 0.36% 113
2015
Q2
$17.1M Buy
313,904
+1,400
+0.4% +$78.5K 0.39% 107
2015
Q1
$17.1M Buy
312,504
+20,850
+7% +$1.18M 0.39% 100
2014
Q4
$15.8M Sell
291,654
-116,345
-29% -$6.48M 0.38% 98
2014
Q3
$23.1M Buy
407,999
+9,214
+2% +$517K 0.61% 70
2014
Q2
$22M Sell
398,785
-4,772
-1% -$260K 0.56% 74
2014
Q1
$21.9M Buy
403,557
+5,346
+1% +$277K 0.59% 74
2013
Q4
$19M Buy
398,211
+3,922
+1% +$179K 0.52% 82
2013
Q3
$17.9M Sell
394,289
-58,596
-13% -$2.68M 0.55% 78
2013
Q2
$20.1M Buy
+452,885
New +$20.2M 0.74% 57

Other funds holding MRK

GW&K Investment Management's MRK Position: Q1 2026 in Review

GW&K Investment Management reduced its Merck (MRK) stake by 96% in Q1 2026, selling an estimated $32.9M and leaving 10,667 shares worth $1.28M. The position accounts for 0.01% of the portfolio, ranked #325.

GW&K Investment Management first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $41.7M in Q1 2019. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • GW&K Investment Management held 10,667 shares of Merck worth $1.28M as of Q1 2026.
  • GW&K Investment Management sold 284,664 Merck shares in Q1 2026, an estimated $32.9M.
  • Merck made up 0.01% of GW&K Investment Management's portfolio in Q1 2026, its #325 holding.
  • GW&K Investment Management first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • GW&K Investment Management's Merck position peaked at $41.7M in Q1 2019.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.